-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune Checkpoint Inhibitors (ICIs) can restore the proliferation and effect of T cells, snipe escaping tumor cells, and are currently hot star drugs in the field of solid tumors and hematological tumors
.
But it can produce immune-related adverse events (irAEs)
.
IrAEs can affect any tissue or organ, and if they are handled improperly, they can directly affect the survival benefit of anti-tumor drugs
But it is very similar to AEs caused by chemotherapy, targeted therapy or infection, and it is not easy to distinguish them completely
.
In this regard, some scholars recently proposed that ferritin can be used as a marker for the diagnosis, differential diagnosis and prognosis of IrAEs
Ferritin can be used as a marker for the diagnosis, differential diagnosis and prognosis of IrAEs
On Cancer Biol Med
Research methods
Research methodsThe researchers included a total of 318 patients with malignant tumors, of which 231 patients were receiving PD-1 inhibitors or combined chemotherapy, and 87 patients were receiving chemotherapy only
.
Among the 231 patients, they can be divided into irAE group (90 people with irAE), non-irAE group (70 people without irAE), AE group (4 people with AE) and non-irAE-no AE group (67 people, Neither irAE nor AE)
.Among the 87 patients, they can be divided into an AE group (60 people, with AE) and a non-AE group (27 people, without AE)
.
Among the 231 patients, they can be divided into irAE group (90 people with irAE), non-irAE group (70 people without irAE), AE group (4 people with AE) and non-irAE-no AE group (67 people, Neither irAE nor AE)
.
Among the 87 patients, they can be divided into an AE group (60 people, with AE) and a non-AE group (27 people, without AE)
.
Analysis conclusion
Analysis conclusionThrough 4 months of serum ferritin monitoring, it was found that:
When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L
.When adverse events occurred in the irAE group, the ferritin content was significantly higher than that of the non-irAE group and the AE group
.At the same time, the researchers also found that after treatment in the irAE group, the ferritin content of the patients will gradually drop to the normal range
.
When adverse events occurred in the irAE group, the ferritin content (normal range 35-150μg/L) rose from the baseline value of 86μg/L to the median value of 927μg/L
.
.
When adverse events occurred in the irAE group, the ferritin content was significantly higher than that of the non-irAE group and the AE group
.
.
At the same time, the researchers also found that after treatment in the irAE group, the ferritin content of the patients will gradually drop to the normal range
.
.
It can be seen that ferritin is a marker that can determine whether a patient has irAE and prognosis
.
Literature source :
Literature sourceWeihong Zhang, et al.
Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events.
Leave a message here
